Danielle joined Drug Discovery News as a freelance science writer in 2021. She earned her PhD from Yale University in 2017 and is currently a postdoctoral researcher at Weill Cornell Medicine where she studies the effects of early life stress on brain development. Danielle has written about many topics, including antimicrobial resistance, mitochondrial disease, and the first transgenic mice. In her spare time, Danielle enjoys baking, knitting, and hiking.
Articles by Danielle Gerhard, PhD
Antimicrobial resistance poses a significant threat to healthcare. Ultra-microscopic viruses called bacteriophages might hold a solution.
| 1 min read
Transgenic mice play pivotal roles in scientific and therapeutic discovery, but how did they become a staple model system?
| 5 min read
Katalin Karikó and Drew Weissman received this year’s Physiology or Medicine award for their work on RNA biology and mRNA-based vaccines.
Herceptin transformed breast cancer treatment and opened the door to targeted therapy.
| 9 min read
This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.
| 6 min read
A team of industry and academic researchers developed a new way to engineer the immune
system, leading to the first clinical trial using genetically modified macrophages.
The pioneering immunology discoveries that birthed CAR T cell therapy and reshaped the battle against cancer.
| 7 min read
Mixed messages surrounding their clinical benefits threatened the legitimacy of stem cell therapies for multiple sclerosis, but there is still plenty of promise.
| 6 min read
A new oral bead technology is designed to stimulate nutrient-sensing cells in discrete parts of the gut to restore metabolic balance.
| 4 min read
A novel, non-invasive treatment using electrical currents exploits physiological properties of dividing cancer cells to prolong survival and augment current therapies.
Conserved across plants and animals, RNAi is a powerful mechanism with tremendous therapeutic potential.
| 6 min read
Recent advancements in mitochondrial genome editing technologies take scientists one step closer to developing viable treatments for mitochondrial diseases, which affect 1 in 4300 adults.
